News | January 14, 2008

Ablation System for AF Earns 82 Percent Success Rate

January 15, 2008 - Surgeons and electrophysiologists who used AtriCure's endoscopic bipolar ablation system to treat atrial fibrillation (AF) said the procedure was successful in 82 percent of patients that presented with paroxysmal AF and 56 percent of patients that presented with persistent and long-standing persistent AF in a report published in the Journal of Interventional Cardiac Electrophysiology.

The authors of the study, James R. Edgerton, M.D., and Michael B. Mack,M.D., from the Cardiopulmonary Research Science and Technology Institute of Dallas, Texas in collaboration with Warren M. Jackman, M.D., an electrophysiologist from the University of Oklahoma, reported on results from 83 patients who underwent a video-assisted, minimally invasive ablation procedure for the treatment of AF using AtriCure's Isolator endoscopic bipolar ablation system. The procedure included electrical isolation of the pulmonary veins, confirmed by electrophysiology mapping techniques, targeted autonomic denervation of the left atrium and the removal of the left atrial appendage in selected patients. The study population consisted of patients with left atrial enlargement as the authors reported a mean left atrial size of 5.2cm. Left atrial enlargement is known to be one of the primary predictors of ablation failures. Additionally, 25 percent of the patients had at least one previous catheter ablation failure.

Of the 83 patients, 57 completed long-term monitoring at 6 months. Treatment success was defined as no episodes of AF greater than 15 seconds in duration. The minimally invasive procedure was successful in 32 of 39 (82 percent) of patients that presented with paroxysmal AF and 10 of 18 (56 percent) of patients that presented with persistent and long-standing persistent AF.

Dr. Edgerton commented, "The results from this study are very encouraging and support the safety and effectiveness of this procedure and products in a selected group of AF patients. We remain enthusiastic concerning the continued development and investigation of these minimally invasive products and techniques. In particular, we have developed an expanded ablation procedure and we are encouraged by the potential for the expanded ablation procedure to improve clinical outcomes in the more difficult to treat persistent and permanent AF patients."

For more information: www.atricure.com


Related Content

News

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News

Oct. 18, 2024 — Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
News

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Subscribe Now